{
  "pmcid": "11593991",
  "sha256": "bd1ce57807204cd3b6fbc9e4b29f8a400a36b1a2ee781634cc8b9083f7028f5b",
  "timestamp_utc": "2025-11-09T22:05:21.686645+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.809544683257919,
    "reading_ease": 27.826172228506806,
    "word_count": 221
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial of TGF-β Signaling Inhibition in AVF Patency in CKD"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed."
      },
      "Participants": {
        "score": 2,
        "evidence": "This randomised controlled trial involved C57BL/6J mice subjected to 5/6 nephrectomy to induce CKD, with 0/6 and 3/6 nephrectomy as controls."
      },
      "Intervention": {
        "score": 2,
        "evidence": "AVF were created in mice with TGF-βR1/R2 knockdown in endothelial or smooth muscle cells."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates whether inhibiting endothelial TGF-β signaling can prevent AVF failure by reducing endothelial-to-mesenchymal transition (EndMT)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was AVF patency, assessed over 42 days."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "120 mice were randomised: 60 to the intervention and 60 to the control group."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Inhibition of TGF-β signaling decreased smooth muscle cell proliferation, reduced wall thickness, and improved AVF patency."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by NIH grants R01-HL128406, R01-HL144476, R01-HL162580, R01-HL152197, R01-HL146723, R01-HL155105, China Scholarship Council, and VA Connecticut Healthcare System."
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}